Literature DB >> 68204

Treatment of melanoma by passive humoral immunotherapy using antibody drug synergism.

K D Everall, P Dowd, D A Davies, G J O'Neill, G F Rowland.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1977        PMID： 68204     DOI： 10.1016/s0140-6736(77)92359-5

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  5 in total

Review 1.  The role of immunotherapy in the management of patients with malignant melanoma.

Authors:  J E Goodnight; D L Morton
Journal:  World J Surg       Date:  1979-07-30       Impact factor: 3.352

Review 2.  Combined modality therapy of malignant melanoma.

Authors:  E M Hersh; J U Gutterman; C M McBride
Journal:  World J Surg       Date:  1979-07-30       Impact factor: 3.352

Review 3.  Antibody-targeted polymer-bound drugs.

Authors:  B Ríhová
Journal:  Folia Microbiol (Praha)       Date:  1995       Impact factor: 2.099

Review 4.  Oncostatic-antibody complexes in chemotherapy.

Authors:  H F Dullens; R A De Weger
Journal:  Cancer Chemother Pharmacol       Date:  1980       Impact factor: 3.333

5.  Preparation and characterization of an antiserum to cultured human oat-cell carcinoma cells.

Authors:  C E Newman; C H Ford; E Parkes
Journal:  Br J Cancer       Date:  1978-05       Impact factor: 7.640
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.